vs
CollPlant Biotechnologies Ltd（CLGN）与捷迈邦美（ZBH）财务数据对比。点击上方公司名可切换其他公司
捷迈邦美的季度营收约是CollPlant Biotechnologies Ltd的12534.6倍（$2.2B vs $179.0K）。捷迈邦美净利率更高（6.2% vs -1869.8%，领先1876.0%）。捷迈邦美同比增速更快（10.9% vs -28.1%）
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
捷迈邦美是一家美国上市的医疗设备企业，1927年成立，最初以生产铝制夹板为核心业务，总部设于印第安纳州华沙市，是当地医疗设备产业集群的核心成员，在全球骨科医疗器械领域拥有较高知名度。
CLGN vs ZBH — 直观对比
营收规模更大
ZBH
是对方的12534.6倍
$179.0K
营收增速更快
ZBH
高出39.0%
-28.1%
净利率更高
ZBH
高出1876.0%
-1869.8%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $179.0K | $2.2B |
| 净利润 | $-3.3M | $139.4M |
| 毛利率 | -3.9% | 64.7% |
| 营业利润率 | -1775.4% | 6.9% |
| 净利率 | -1869.8% | 6.2% |
| 营收同比 | -28.1% | 10.9% |
| 净利润同比 | 20.5% | -41.8% |
| 每股收益（稀释后） | $0.28 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLGNZBH
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | $179.0K | $2.1B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $249.0K | $1.9B | ||
| Q1 24 | — | $1.9B |
净利润CLGNZBH
| Q4 25 | — | $139.4M | ||
| Q3 25 | — | $230.9M | ||
| Q2 25 | $-3.3M | $152.8M | ||
| Q1 25 | — | $182.0M | ||
| Q4 24 | — | $239.5M | ||
| Q3 24 | — | $249.1M | ||
| Q2 24 | $-4.2M | $242.8M | ||
| Q1 24 | — | $172.4M |
毛利率CLGNZBH
| Q4 25 | — | 64.7% | ||
| Q3 25 | — | 72.1% | ||
| Q2 25 | -3.9% | 71.5% | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | — | 71.0% | ||
| Q3 24 | — | 70.5% | ||
| Q2 24 | -115.3% | 71.5% | ||
| Q1 24 | — | 72.9% |
营业利润率CLGNZBH
| Q4 25 | — | 6.9% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | -1775.4% | 14.4% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 19.2% | ||
| Q3 24 | — | 15.3% | ||
| Q2 24 | -1769.5% | 18.1% | ||
| Q1 24 | — | 14.1% |
净利率CLGNZBH
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | -1869.8% | 7.4% | ||
| Q1 25 | — | 9.5% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | -1690.8% | 12.5% | ||
| Q1 24 | — | 9.1% |
每股收益（稀释后）CLGNZBH
| Q4 25 | — | $0.71 | ||
| Q3 25 | — | $1.16 | ||
| Q2 25 | $0.28 | $0.77 | ||
| Q1 25 | — | $0.91 | ||
| Q4 24 | — | $1.18 | ||
| Q3 24 | — | $1.23 | ||
| Q2 24 | $0.37 | $1.18 | ||
| Q1 24 | — | $0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4M | $591.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.5M | $12.7B |
| 总资产 | $17.4M | $23.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLGNZBH
| Q4 25 | — | $591.9M | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $11.4M | $556.9M | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $569.0M | ||
| Q2 24 | $18.9M | $420.1M | ||
| Q1 24 | — | $393.0M |
股东权益CLGNZBH
| Q4 25 | — | $12.7B | ||
| Q3 25 | — | $12.8B | ||
| Q2 25 | $12.5M | $12.5B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $12.5B | ||
| Q3 24 | — | $12.4B | ||
| Q2 24 | $20.7M | $12.7B | ||
| Q1 24 | — | $12.6B |
总资产CLGNZBH
| Q4 25 | — | $23.1B | ||
| Q3 25 | — | $23.5B | ||
| Q2 25 | $17.4M | $22.9B | ||
| Q1 25 | — | $22.2B | ||
| Q4 24 | — | $21.4B | ||
| Q3 24 | — | $21.7B | ||
| Q2 24 | $26.6M | $21.5B | ||
| Q1 24 | — | $21.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $517.4M |
| 自由现金流经营现金流 - 资本支出 | — | $442.6M |
| 自由现金流率自由现金流/营收 | — | 19.7% |
| 资本支出强度资本支出/营收 | — | 3.3% |
| 现金转化率经营现金流/净利润 | — | 3.71× |
| 过去12个月自由现金流最近4个季度 | — | $1.5B |
8季度趋势，按日历期对齐
经营现金流CLGNZBH
| Q4 25 | — | $517.4M | ||
| Q3 25 | — | $418.7M | ||
| Q2 25 | — | $378.2M | ||
| Q1 25 | — | $382.8M | ||
| Q4 24 | — | $506.3M | ||
| Q3 24 | — | $395.7M | ||
| Q2 24 | — | $369.4M | ||
| Q1 24 | — | $228.0M |
自由现金流CLGNZBH
| Q4 25 | — | $442.6M | ||
| Q3 25 | — | $363.7M | ||
| Q2 25 | — | $328.1M | ||
| Q1 25 | — | $338.2M | ||
| Q4 24 | — | $454.8M | ||
| Q3 24 | — | $351.2M | ||
| Q2 24 | — | $316.7M | ||
| Q1 24 | — | $172.9M |
自由现金流率CLGNZBH
| Q4 25 | — | 19.7% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 15.8% | ||
| Q1 25 | — | 17.7% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | — | 19.3% | ||
| Q2 24 | — | 16.3% | ||
| Q1 24 | — | 9.2% |
资本支出强度CLGNZBH
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 2.9% |
现金转化率CLGNZBH
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | 1.81× | ||
| Q2 25 | — | 2.48× | ||
| Q1 25 | — | 2.10× | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | — | 1.59× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLGN
暂无分部数据
ZBH
| Knees | $911.0M | 41% |
| SET | $587.6M | 26% |
| Hips | $555.4M | 25% |
| Technology And Data Bone Cement And Surgical | $189.8M | 8% |
